P.48 Procoagulant phospholipids clotting time in normal pregnancy and preeclampsia

Abstract

s / Thrombosis Research 127 (2011) S123–S150 S141 disease. Undifferentiated thrombocytopathy was diagnosed in 11 (15.7%) of women. In control group undifferentiated thrombocytopathy was found in 5 (3.8%) of women, von Willebrand’s disease was not detected < 0.05). – 23 (32.9%) of the women had a thrombophilia: genetic 18 (25.7%) or combined one (combination of genetic thrombophilia with AFA circulation) 5 (7.4%). In control group thrombophilia was found in 9 (6.9%) of women (p < 0.05). – The 26 (37.1%) of women had the thrombophilic disorders in combination with the defects of platelet function. There are no women in control group had combination of thrombophilic and haemorrhagical disorders (p < 0.05). 25 women evaluated prospectively received differentiated pathogenetic therapy and prophylaxis, according to the diagnosed condition. All women delivered live babies without any cases of obstetrical haemorrhage. Conclusion: the presence of undetectable haemostasis system defects such as thrombophilia, platelet function defects and their combination can essentially increase risk of severe haemorrhagical complication during pregnancy. P.48 Procoagulant phospholipids clotting time in normal pregnancy and preeclampsia L. Spiezia *, E. Campello, M. Bon, S. Gavasso, S. Visentin, E. Cosmi, B. Woodhams, P. Simioni. Department of Cardiologic, Thoracic, and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Gynaecological Science and Human Reproduction, Section of Maternal Foetal Medicine, University of Padua School of Medicine, Padua, Italy, R&D, Diagnostica Stago, Gennevilliers, France Background: We performed a case control study to evaluate the changes in procoagulant phospholipids depending clotting time (PPL-CT) during normal pregnancy and in preeclampsia. PPL activity was evaluated using a specific clotting assay designed to measure the influence of phospholipids on the activation of coagulation cascade. Patients and Methods: One hundred and ten women were enrolled: 25 non-pregnant women (control), 35 women in the first (T1, n = 10), second (T2, n = 10) and third (T3, n = 15) trimesters of pregnancy, 25 during labour (L) and 25 women with preeclampsia. After informed consent blood samples (1:10 dilution in 0.105M buffered Na-citrate) were collected and double centrifuged. The PPL-CT (STA Procoagulant PPL, Diagnostica Stago, France) is obtained by measuring the CT of the patient sample, diluted in phospholipid depleted substrate plasma, after activation by Factor Xa. A shortening CT of the sample compared with control values means an increase in PPL